Post-Conference Perspectives: Updates in HER2+ Metastatic Breast Cancer; ASCO 2023 Highlights - Episode 2
Data Updates from SABCS 2022 in HER2+ Metastatic Breast Cancer
An expert on HER2+ metastatic breast cancer reviews data from the DESTINY-Breast02 and DESTINY-Breast03 trials, which were updated at the 2022 San Antonio Breast Cancer Symposium.
Transcript:
Megan Kruse, MD: Now we’ll talk about some new data updates from last year for the management of HER2-positive metastatic breast cancer.
The first abstract we’ll talk about today is from the San Antonio Breast Cancer Symposium in 2022. This is the update from DESTINY-Breast02 (NCT03523585), which is the comparison of trastuzumab deruxtecan, or T-DXd, to the treatment of physician’s choice in the treatment of metastatic HER2-positive breast cancer following treatment with ado-trastuzumab emtansine. In the update from this presentation, we saw this data previously in terms of the activity of trastuzumab deruxtecan in this space. This update really showed us that those initial results that we saw continued to be valid with longer follow-up. We saw a very significant improvement in response rate, as well as progression-free survival for trastuzumab deruxtecan compared to treatment of physician’s choice, which in this study was either combination of capecitabine and lapatinib or capecitabine and trastuzumab. The update shows us that trastuzumab deruxtecan has a large role in the management of HER2-positive metastatic breast cancer. And that role only got stronger as the year went on and we saw updates from other data.
The next abstract, also from San Antonio Breast Cancer Symposium 2022, was the update of the DESTINY-Breast03 (NCT03529110) study. This is looking at the use of trastuzumab deruxtecan, this time in comparison with second-line treatment with trastuzumab emtansine for patients with metastatic HER2-positive breast cancer.
What we saw with this abstract was a continued improvement in progression-free survival, as was originally seen in the first data presentation from this study, in favor of trastuzumab deruxtecan. There was about a 4-fold improvement in progression-free survival in favor of trastuzumab deruxtecan compared to trastuzumab emtansine. But, what was new was an improvement in overall survival [results], again favoring trastuzumab deruxtecan compared to the prior standard of care of T-DM1.
Transcript edited for clarity.
Related Content:
